Parkinson Disease Clinical Trials

117 studies are recruiting for parkinson disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control

   In this study the investigators aim to enroll patients scheduled to undergo deep brain stimulation (DBS) implantation for movement disorders for intra-operative testing. In addition to standard-of-care surgical procedure to implant deep brain stimulation electrode leads, participants will also be s…

   Stage

   Not phased

   Ages

   18 to 75

   Site

   University of Pittsburgh, Pittsburgh, Pennsylvania

   Run by

   Jorge Gonzalez-Martinez

   See if you can join NCT07056361 on ClinicalTrials.gov

2. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

   A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.

   Stage

   Phase 2

   Ages

   40 to 80

   Site

   Site-049, Birmingham, Alabama

   Locations

   22 in total

   Run by

   Biohaven Therapeutics Ltd.

   See if you can join NCT06976268 on ClinicalTrials.gov

3. Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

   The purpose of this study is to determine the changes in quality of life and degree of tremor for patients with essential tremor or Parkinsonian tremor who are treated by stereotactic radiosurgery (SRS). This is a questionnaire-based study. Please see Detailed Description below for more information.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Run by

   Vanderbilt University Medical Center

   See if you can join NCT01734122 on ClinicalTrials.gov

4. Dual Frequency Stimulation in Parkinson's Disease

   Deep brain stimulation (DBS) in the dorsal region of the subthalamic nucleus (STN) is very effective for reducing motor symptoms of Parkinson's disease (PD). Modeling studies suggest that this therapy may result in current spread into the ventral STN, causing altered cognitive processes. As a resul…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UC Davis Health, Sacramento, California

   Run by

   University of California, Davis

   See if you can join NCT04650932 on ClinicalTrials.gov

5. Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease

   Dysphagia, or difficulty swallowing, is a common symptom of many neurological diseases but its treatment is not well established or easily accessible. To start addressing this gap, the researchers developed and validated a cost-effective wearable surface electromyography (sEMG) biofeedback sensor t…

   Stage

   Phase 2

   Ages

   50 to 90

   Site

   University of Illinois Urbana-Champaign, Champaign, Illinois

   Locations

   2 in total

   Run by

   University of Illinois at Urbana-Champaign

   See if you can join NCT06638944 on ClinicalTrials.gov

6. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

   This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo. The study will last about 12 weeks. P…

   Stage

   Phase 2

   Ages

   30 to 80

   Site

   Profound Research LLC (Site #222), Carlsbad, California

   Locations

   30 in total

   Run by

   Appello Pharmaceuticals, Inc.

   See if you can join NCT07432958 on ClinicalTrials.gov

7. Parkinson Progression Marker Initiative Online (PPMI Online)

   Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD. PPMI Online is part of the broader Parki…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UCSF Movement Disorders and Neuromodulation Center (MDNC), San Francisco, California

   Run by

   Michael J. Fox Foundation for Parkinson's Research

   See if you can join NCT05065060 on ClinicalTrials.gov

8. Deep Brain Stimulation (DBS) Retrospective Outcomes Study

   The primary objective of this study is to characterize real-world clinical outcomes of Deep Brain Stimulation (DBS) using retrospective review of de-identified patient records.

   Stage

   Not phased

   Ages

   Any age

   Site

   St. Joseph's Hospital & Medical Center, Phoenix, Arizona

   Locations

   20 in total

   Run by

   Boston Scientific Corporation

   See if you can join NCT03664609 on ClinicalTrials.gov

9. Cortical Electrophysiology of Response Inhibition in Parkinson's Disease

   Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that invol…

   Stage

   Phase 4

   Ages

   45 to 75

   Site

   Emory University Hospital, Atlanta, Georgia

   Locations

   2 in total

   Run by

   Emory University

   See if you can join NCT06234995 on ClinicalTrials.gov

10. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic p…

    Stage

    Phase 2

    Ages

    40 to 80

    Site

    Banner Sun Health Research Institute, Sun City, Arizona

    Locations

    72 in total

    Run by

    Neuron23 Inc.

    See if you can join NCT06680830 on ClinicalTrials.gov

11. Deep Brain Stimulation Neural Recordings of Varied Stimulation During Sleep in Parkinson's Disease

    This study employs an exploratory, prospective, single center, naturalistic clinical trial design with a randomized crossover intervention.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Cleveland Clinic, Cleveland, Ohio

    Run by

    The Cleveland Clinic

    See if you can join NCT07110376 on ClinicalTrials.gov

12. Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

    The goal of this clinical trial is two-fold. First to investigate the feasibility of whether a remotely administered smartphone app can increase the volume and intensity of physical activity in daily life in individuals with a LRRK2 G2019S or GBA1 N370S genetic mutation over a long period of time (…

    Stage

    Not phased

    Ages

    50 and older

    Site

    University of Rochester Center for Health and Technology (CHeT), Rochester, New York

    Locations

    2 in total

    Run by

    Radboud University Medical Center

    See if you can join NCT06993142 on ClinicalTrials.gov

13. Accelerated rTMS for Apathy in Parkinson's Disease

    This single-site, open-label pilot study will evaluate the feasibility, tolerability, and preliminary efficacy of accelerated intermittent theta-burst stimulation (iTBS) targeting the dorsomedial prefrontal cortex (dmPFC) for apathy in individuals with Parkinson's Disease (PD). Fifteen participants…

    Stage

    Not phased

    Ages

    45 to 85

    Site

    Medical University of South Carolina, Charleston, South Carolina

    Run by

    Medical University of South Carolina

    See if you can join NCT07399496 on ClinicalTrials.gov

14. A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's

    The purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD.

    Stage

    Phase 3

    Ages

    22 and older

    Site

    Northwestern University, Evanston, Illinois

    Run by

    Northwestern University

    See if you can join NCT04664634 on ClinicalTrials.gov

15. Correlation of STN-DBS Induced Visuospatial Changes and Freezing of Gait

    The purpose of this research is to determine how deep brain stimulation (DBS) for Parkinson's disease affects attention and visuospatial function. Additionally, this study will evaluate how deficits in visual attention are associated with freezing of gait (FOG) in Parkinson's disease. There is curr…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Medical University of South Carolina, Charleston, South Carolina

    Run by

    Medical University of South Carolina

    See if you can join NCT06994728 on ClinicalTrials.gov

16. Genetics and Aerobic Exercise to Slow Parkinson's Disease Trial

    The proposed multi-site, Genetics and Aerobic Exercise to Slow PD (GEARS) Trial will, for the first time, determine the interplay between genetics and exercise in altering PD progression. In sum, 200 PD patients will be recruited from the Cleveland and Salt Lake City metro areas to participate in t…

    Stage

    Not phased

    Ages

    18 and older

    Site

    The Cleveland Clinic, Cleveland, Ohio

    Run by

    Jay Alberts

    See if you can join NCT06442033 on ClinicalTrials.gov

17. Cross-System Effects of Acute Intermittent Hypercapnia-Based Interventions in PD

    Parkinsonism impairs upper airway and axial motor control, leading to disordered breathing, reduced speech volume, and ineffective cough. Symptoms are poorly addressed by current therapies. This randomized pilot trial tests whether a single session of acute intermittent hypercapnic hypoxia (AIHH) o…

    Stage

    Not phased

    Ages

    40 to 75

    Site

    University of Florida, Gainesville, Florida

    Locations

    2 in total

    Run by

    University of Florida

    See if you can join NCT07674264 on ClinicalTrials.gov

18. Personalized Real-Time DBS and PD Mechanisms

    A prospective cohort of patients scheduled to undergo deep brain stimulation (DBS) implantation surgery for the treatment of Parkinson's disease as per standard of care will be invited to participate in this study. This mechanistic study is aimed at better understanding the role of basal ganglia be…

    Stage

    Phase 4

    Ages

    18 to 80

    Site

    Cleveland Clinic, Cleveland, Ohio

    Run by

    David Escobar

    See if you can join NCT06013956 on ClinicalTrials.gov

19. Using the EHR to Advance Genomic Medicine Across a Diverse Health System

    Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Penn Medicine, Philadelphia, Pennsylvania

    Run by

    University of Pennsylvania

    See if you can join NCT06377033 on ClinicalTrials.gov

20. A Pilot Study of In-lab Dynamic Standing in Parkinson's Disease

    This research is studying the use of a new type of standing desk in a small number of people to learn about the user experience for people with Parkinson's disease. 12 4-hour sessions will be performed to test the primary hypothesis that dynamic standing improves gait function compared to static st…

    Stage

    Phase 1

    Ages

    50 and older

    Site

    Domino's Farms, Ann Arbor, Michigan

    Run by

    University of Michigan

    See if you can join NCT07543861 on ClinicalTrials.gov

21. The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

    The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET ligand [18F]DPA-714 in participants enrolled in the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) and …

    Stage

    Phase 1

    Ages

    30 and older

    Site

    UAB Advanced Imaging Facility, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT03457493 on ClinicalTrials.gov

22. Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)

    The overall goal of this protocol is to investigate [18F]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in [18F]DPA-714 binding in PD participants during a 24-month interval. Primary Objectives * To compare [18F]DPA-71…

    Stage

    EARLY_Phase 1

    Ages

    18 to 99

    Site

    UAB, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT06289582 on ClinicalTrials.gov

23. Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms

    Young Onset Parkinson's disease (YOPD) refers to a group of patients in which the disease starts earlier in life (before the age of 50 years) and has a profound impact on most of patient's life. Current knowledge regarding the mechanisms leading to development of Parkinson's disease in younger indi…

    Stage

    Not phased

    Ages

    18 and older

    Site

    NYU Langone Health, New York, New York

    Run by

    NYU Langone Health

    See if you can join NCT07752355 on ClinicalTrials.gov

24. Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

    A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).

    Stage

    Phase 2

    Ages

    40 to 80

    Site

    The Parkinson's & Movement Disorder Institute, Fountain Valley, California

    Locations

    5 in total

    Run by

    Hillhurst Biopharmaceuticals, Inc.

    See if you can join NCT07005180 on ClinicalTrials.gov

25. Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

    It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-[18…

    Stage

    Phase 4

    Ages

    50 to 85

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT05357612 on ClinicalTrials.gov